Merrill keeps ICOS at neutral

ICOS Corp. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende on news the company filed for E.U. approval of Cialis once daily dosing, going beyond its current as needed dosing. The analyst does not believe the new dosing regimen will impact sales. Merrill raised its 2007 earnings per share estimate to $0.52 from a loss of $0.09, and its 2008 earnings per share to $1.11 from $0.23. Shares of the Bothell, Wash.-based biotechnology company were up 24 cents or 1.11%, at $21.83 on volume of 946,911 shares versus the three-month running average of 807,771 shares. (Nasdaq: ICOS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.